ARCH Venture Management, LLC — 13F Holdings & Portfolio
CIK 1274403 · latest 13F-HR filed 2026-05-15
ARCH Venture Management, LLC manages $677.1M in 13F-reported U.S. long-equity assets across 10 reported positions as of its 2026-03-31 13F-HR filing. Its largest disclosed positions are MAZE (18.16%), RAPP (17.23%), VIR (17.09%). Quarter over quarter (versus its 2025-12-31 filing) the fund opened 1 new position, exited 0, added to 3, and trimmed 5.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
$677.1M
Long-equity book
10
Distinct positions
2026-03-31
Filed 2026-05-15
+1 / −0 / ↑3 / ↓5
vs 2025-12-31
| Name | Title / Status | Ownership | Type |
|---|
Top Adds (vs prior quarter)
- ERASCA INC$73.6M +179.0%
- VIR BIOTECHNOLOGY INC$37.8M +48.6%
- Q32 BIO INC$993.5K +93.4%
Top Trims
- MAZE THERAPEUTICS INC-$47.7M -28.0%
- GOSSAMER BIO INC-$22.3M -89.4%
- LYELL IMMUNOPHARMA INC-$19.8M -23.3%
- BEAM THERAPEUTICS INC-$17.7M -14.0%
- 10X GENOMICS INC-$7.4M -61.6%
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | MAZE THERAPEUTICS INC | MAZE | 578784100 | $123.0M | 18.16% | 4,120,053 | SH |
| 2 | RAPPORT THERAPEUTICS INC | RAPP | 75383L102 | $116.7M | 17.23% | 3,728,738 | SH |
| 3 | VIR BIOTECHNOLOGY INC | VIR | 92764N102 | $115.7M | 17.09% | 12,916,663 | SH |
| 4 | ERASCA INC | ERAS | 29479A108 | $114.7M | 16.95% | 7,091,557 | SH |
| 5 | BEAM THERAPEUTICS INC | BEAM | 07373V105 | $108.2M | 15.98% | 4,540,132 | SH |
| 6 | LYELL IMMUNOPHARMA INC | LYEL | 55083R203 | $65.1M | 9.62% | 3,247,162 | SH |
| 7 | GENERATE BIOMEDICINES INC | GENB | 370920100 | $24.3M | 3.59% | 1,944,426 | SH |
| 8 | 10X GENOMICS INC | TXG | 88025U109 | $4.6M | 0.68% | 217,834 | SH |
| 9 | GOSSAMER BIO INC | GOSS | 38341P102 | $2.6M | 0.39% | 8,055,916 | SH |
| 10 | Q32 BIO INC | QTTB | 746964105 | $2.1M | 0.30% | 320,482 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-03-31 | 2026-05-15 | $677.1M | 10 | 0001012975-26-000461 |
| 2025-12-31 | 2026-02-17 | $651.7M | 9 | 0001012975-26-000153 |
| 2025-09-30 | 2025-11-14 | $492.4M | 9 | 0001012975-25-000787 |